Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Neurocrine Biosciences, Inc. (NBIX) had Normalized Income after Taxes of $116.38M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$687.50M |
|
$107.50M |
|
$11.30M |
|
$676.20M |
|
$541.90M |
|
$145.60M |
|
$13.90M |
|
$159.50M |
|
$166.20M |
|
$107.50M |
|
$107.50M |
|
$107.50M |
|
|
Normalized Income after Taxes |
$116.38M |
$145.60M |
|
$152.90M |
|
99.00M |
|
101.00M |
|
$1.09 |
|
$1.06 |
|
| Balance Sheet Financials | |
$1.75B |
|
$91.70M |
|
$2.14B |
|
$3.89B |
|
$546.30M |
|
-- |
|
$649.20M |
|
$1.20B |
|
$2.69B |
|
$2.66B |
|
$2.69B |
|
99.00M |
|
| Cash Flow Statement Financials | |
$166.80M |
|
$-14.80M |
|
$-121.20M |
|
$241.00M |
|
$272.00M |
|
$31.00M |
|
$105.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
98.36% |
|
21.18% |
|
21.18% |
|
-- |
|
23.20% |
|
15.64% |
|
$143.60M |
|
-- |
|
-- |
|
-- |
|
0.18 |
|
0.20 |
|
1.15 |
|
77.98 |
|
3.99% |
|
4.05% |
|
2.76% |
|
3.99% |
|
$27.22 |
|
$1.42 |
|
$1.65 |
|